Zacks Investment Research on MSN
Can Amgen's Maritide take on leaders in the obesity space?
Amgen AMGN is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing ...
Clinical Trials Arena on MSN
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial.
Futurism on MSN
People Jabbing Themselves With Black Market “GLP-3” Drugs
People have been losing weight on retatrutide, more powerful than GLP-1 agonist drugs, but they are buying them from ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, ...
A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors and sometimes eliminating them entirely.
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, ...
Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a ...
Rachael Link is a registered dietitian and health writer based in San Francisco. She completed her undergraduate degree at the University of Central Missouri and holds a master’s degree from New York ...
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback